NRC FORM 591M PART 1
(07-2012)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
InnerVision Advanced Medical Imaging 3801 Amelia Avenue Suite A Lafayette, Indiana 47905 REPORT NUMBER(S) 2016-001	Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-~~35553~~ 35552	13-32273-01	May 23, 2016

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☒ 1. Based on the inspection findings, no violations were identified.

☐ 2. Previous violation(s) closed.

☐ 3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

_____ Non-cited violation(s) were discussed involving the following requirement(s):

☐ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Geoffrey M. Warren		5/23/16
BRANCH CHIEF	Aaron T. McCraw		6/3/16

NRC FORM 591M PART 3
(07-2012)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
InnerVision Advanced Medical Imaging 3801 Amelia Avenue Suite A Lafayette, Indiana 47905 REPORT NUMBER(S) 2016-001	Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-35552	13-32273-01	May 23, 2016

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87131	03.01 - 03.09

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
02200	3	Kent T. Lancaster, M.D., RSO	(765) 447-7447

☑ Main Office Inspection Next Inspection Date: May 2019

☐ Field Office Inspection

☐ Temporary Job Site Inspection

PROGRAM SCOPE

This was a routine, unannounced, inspection. The licensee was a nuclear medicine clinic located in Lafayette, Indiana, with authorization to use byproduct materials in Sections 35.100, 35.200, and 35.300. Licensed activities were conducted only at the location indicated on the license. The nuclear medicine department was staffed with three part-time nuclear medicine technologists. The licensee's nuclear medicine staff typically administered 100 diagnostic doses monthly, including positron emission tomography (PET) and a variety of imaging procedures. Therapeutic procedures included around six radium-223 chloride procedures annually and occasional iodine-131 procedures. Doses were received as unit doses or bulk fluorine-18 FDG from licensed nuclear pharmacies. The bulk fluorine-18 FDG was used in a multidose administration system. All waste was either held for decay-in-storage (DIS) or returned to the nuclear pharmacy.

Performance Observations: At the time of the inspection, the licensee had completed administrations of licensed materials for the day. The inspector observed the daily contamination survey. Licensee personnel demonstrated morning checks, package receipt and return surveys, use of personal protective equipment while handling unsealed materials, and weekly wipes, and described a variety of therapeutic and diagnostic administrations. The inspector reviewed written directives for radiopharmaceutical therapies and identified no concerns. Interviews with licensee personnel indicated adequate knowledge of radiation safety concepts and procedures. Dosimetry records indicated no exposures of regulatory concern. The inspector performed independent and confirmatory radiation measurements which indicated results consistent with licensee survey records and postings.

No violations were identified during this inspection.